Compare DERM & IGA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DERM | IGA |
|---|---|---|
| Founded | 2014 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 190.3M | 162.0M |
| IPO Year | 2021 | N/A |
| Metric | DERM | IGA |
|---|---|---|
| Price | $4.30 | $10.00 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $13.75 | N/A |
| AVG Volume (30 Days) | ★ 193.9K | 45.4K |
| Earning Date | 11-16-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 8.93% |
| EPS Growth | ★ 34.72 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $61,858,000.00 | N/A |
| Revenue This Year | $25.29 | N/A |
| Revenue Next Year | $50.00 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 10.20 | N/A |
| 52 Week Low | $4.31 | $9.21 |
| 52 Week High | $9.56 | $10.77 |
| Indicator | DERM | IGA |
|---|---|---|
| Relative Strength Index (RSI) | 36.54 | 56.77 |
| Support Level | $4.31 | $10.08 |
| Resistance Level | $5.50 | $10.76 |
| Average True Range (ATR) | 0.33 | 0.18 |
| MACD | 0.02 | 0.03 |
| Stochastic Oscillator | 18.50 | 94.30 |
Journey Medical Corp is a commercial-stage pharmaceutical company that focuses on the selling and marketing of U.S. Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its current product portfolio includes FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. The company views its operations and manages its business in one segment, which reflects products for the treatment of dermatological conditions. The dermatological segment derives revenues from the sale of branded and authorized general prescription products that treat certain dermatological conditions.
Voya Global Advantage and Premium Opportunity Fund is a United States-based diversified, closed-end management investment company. The fund has two investment objectives. Its primary objective is to provide a high level of income, while the secondary objective is to seek capital appreciation. To achieve these objectives, the fund invests at least 80% of its managed assets in a portfolio of common stocks from various countries around the world, including the United States. Additionally, it uses an integrated derivatives strategies.